Jason Lettmann's Net Worth
$279 Thousand
Who is Jason Lettmann?
Jason Lettmann does not have any significant net worth to report based on the numbers we have. This is based on reported shares across multiple companies, which include ALX ONCOLOGY HOLDINGS INC, and Ra Pharmaceuticals, Inc..
SEC CIK
Jason Lettmann's CIK is 0001688269
Past Insider Trading and Trends
2024 was Jason Lettmann's most active year for acquiring shares with 3 total transactions. Jason Lettmann's most active month to acquire stocks was the month of May. 2020 was Jason Lettmann's most active year for disposing of shares, totalling 2 transactions. Jason Lettmann's most active month to dispose stocks was the month of June. 2024 saw Jason Lettmann paying a total of $49,771.48 for 254,400 shares, this is the most they've acquired in one year. In 2024 Jason Lettmann cashed out on 2,191 shares for a total of $5,652.78, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
ALX ONCOLOGY HOLDINGS INC (ALXO) Snapshot price: $1.91
CHIEF EXECUTIVE OFFICERJason Lettmann owns 169,429 units of Common Stock which is worth $323,609.39. From 2020 to 2024 Jason Lettmann acquired a total of 153,104 shares in ALX ONCOLOGY HOLDINGS INC at a cost of $49,771.48, Jason also disposed a total of 2,191 shares of ALX ONCOLOGY HOLDINGS INC equalling to $5,652.78.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -1.28% | -2.19K |
$2.58 | -$5,652.78 | 169.43K |
Aug 14
| |||
Form 4
| +2.63% | 4.4K |
$11.31 | $49,771.48 | 171.62K |
Mar 14
| |||
Form 4
| +55.96% | 60K |
—
|
—
| 167.22K |
Feb 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 20
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 15
| |||
Form 4
| -2.22% | -325.38K |
$27.91 | -$8,901,803.95 | 14.36M |
Dec 13
| |||
Form 4
| -0.73% | -145.64K |
$32.17 | -$4,698,091.14 | 19.84M |
Dec 8 - Dec 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 11
| |||
Form 4
| +398.72% | 4.18M |
$19.00 | $7,600,000.00 | 5.23M |
Jul 21
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 16
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Ra Pharmaceuticals, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 20
| |||
Form 4
| +23,622.45% | 4.05M |
$12.11 | -$4,420.00 | 4.07M |
Oct 31
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||